Literature DB >> 15915020

Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study.

Paul F White1, Dajun Song, Joao Abrao, Kevin W Klein, Bryan Navarette.   

Abstract

BACKGROUND: Since the effects of antiemetic doses of droperidol on the QT interval have not been previously studied, the authors designed a randomized, double-blind, placebo-controlled study to evaluate the intraoperative and postoperative effects of small-dose droperidol (0.625 and 1.25 mg intravenous) on the QT interval when used for antiemetic prophylaxis during general anesthesia.
METHODS: One hundred twenty outpatients undergoing otolaryngologic procedures with a standardized general anesthetic technique were enrolled in this study. After anesthetic induction and before the surgical incision, 60 patients were given either saline or 0.625 or 1.25 mg intravenous droperidol in a total volume of 2 ml. A standard electrocardiographic lead II was recorded immediately before and every minute after the injection of the study medication during a 10-min observation period. The QTc (QT interval corrected for heart rate) was evaluated from the recorded electrocardiographic strips. In 60 additional patients, a 12-lead electrocardiogram was obtained before and at specific intervals up to 2 h after surgery to assess the effects of droperidol and general anesthesia on the QTc. Any abnormal heartbeats or arrhythmias during the operation or the subsequent 2-h monitoring interval were also noted.
RESULTS: Intravenous droperidol, 0.625 and 1.25 mg, prolonged the QT interval by an average of 15 +/- 40 and 22 +/- 41 ms, respectively, at 3-6 min after administration during general anesthesia, but these changes did not differ significantly from that seen with saline (12 +/- 35 ms) (all values mean +/- SD). There were no statistically significant differences among the three study groups in the number of patients with greater than 10% prolongation in QTc (vs. baseline). Although general anesthesia was associated with a 14- to 16-ms prolongation of the QTc interval in the early postoperative period, there was no evidence of droperidol-induced QTc prolongation after surgery. Finally, there were no ectopic heartbeats observed on any of the electrocardiographic rhythm strips or 12-lead recordings during the perioperative period.
CONCLUSION: Use of a small dose of droperidol (0.625-1.25 mg intravenous) for antiemetic prophylaxis during general anesthesia was not associated with a statistically significant increase in the QTc interval compared with saline. More importantly, there was no evidence of any droperidol-induced QTc prolongation immediately after surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915020     DOI: 10.1097/00000542-200506000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  19 in total

Review 1.  Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting.

Authors:  Kate McKeage; Dene Simpson; Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Update on the management of postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

3.  Prophylactic antiemetic effects in gynecologic patients receiving fentanyl IV-patient controlled analgesia: comparison of combined treatment with ondansetron and dexamethasone with metoclopramide and dexamethasone.

Authors:  Young Seok Jee; Hea-Jo Yoon; Chang-Ha Jang
Journal:  Korean J Anesthesiol       Date:  2010-11-25

4.  Comparison of dexamethasone with ondansetron or haloperidol for prevention of patient-controlled analgesia-related postoperative nausea and vomiting: a randomized clinical trial.

Authors:  Po-Kai Wang; Pei-Jiuan Tsay; Chia-Chun Huang; Hsien-Yong Lai; Pei-Chin Lin; Shen-Jer Huang; Yi Lee
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

Review 5.  Patient-controlled analgesia in the management of postoperative pain.

Authors:  Mona Momeni; Manuela Crucitti; Marc De Kock
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study.

Authors:  Krzysztof Tracz; Radosław Owczuk
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

7.  Droperidol transiently prolongs the QT interval in children undergoing single ventricle palliation.

Authors:  John P Scott; Eckehard A E Stuth; Astrid G Stucke; Joseph R Cava; Richard J Berens
Journal:  Pediatr Cardiol       Date:  2014-08-03       Impact factor: 1.655

Review 8.  Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy.

Authors:  Tong J Gan
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  [Nausea and vomiting in the postoperative phase. Expert- and evidence-based recommendations for prophylaxis and therapy].

Authors:  C C Apfel; P Kranke; S Piper; D Rüsch; H Kerger; M Steinfath; K Stöcklein; D R Spahn; T Möllhoff; K Danner; A Biedler; M Hohenhaus; B Zwissler; O Danzeisen; H Gerber; F-J Kretz
Journal:  Anaesthesist       Date:  2007-11       Impact factor: 1.041

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.